Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Madrigal Pharmaceuticals, Inc. (MDGL)

150.02   1.07 (0.72%) 09-27 10:50
Open: 149.45 Pre. Close: 148.95
High: 153.52 Low: 149.2
Volume: 42,482 Market Cap: 2,771(M)

Technical analysis

as of: 2023-09-27 10:17:57 AM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 208.95     One year: 234.32
Support: Support1: 143.75    Support2: 119.6
Resistance: Resistance1: 178.89    Resistance2: 200.61
Pivot: 169.92
Moving Average: MA(5): 152.67     MA(20): 173.09
MA(100): 219.96     MA(250): 206.13
MACD: MACD(12,26): -9.6     Signal(9): -7
Stochastic oscillator: %K(14,3): 8.1     %D(3): 5.7
RSI: RSI(14): 32.7
52-week: High: 322.67  Low: 57.2
Average Vol(K): 3-Month: 293 (K)  10-Days: 396 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MDGL ] has closed above bottom band by 18.8%. Bollinger Bands are 66% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 154.05 - 155.53 155.53 - 156.42
Low: 140.71 - 142.58 142.58 - 143.71
Close: 146.76 - 149.87 149.87 - 151.75

Company Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Headline News

Wed, 27 Sep 2023
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93 ... - The Motley Fool

Tue, 26 Sep 2023
Commit To Purchase Madrigal Pharmaceuticals At $140, Earn 32.4 ... - Nasdaq

Mon, 25 Sep 2023
Madrigal Pharma chief commercial officer leaving; shares down 3% - Seeking Alpha

Thu, 21 Sep 2023
Notable Thursday Option Activity: NET, SMCI, MDGL - Nasdaq

Thu, 21 Sep 2023
Weight-Loss Drugs Are Bad News for These Stocks - Barrons - Barron's

Wed, 20 Sep 2023
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 18 (M)
Shares Float 11 (M)
% Held by Insiders 9.8 (%)
% Held by Institutions 85 (%)
Shares Short 1,960 (K)
Shares Short P.Month 1,830 (K)

Stock Financials

EPS -18.43
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.61
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -79.7
Return on Equity (ttm) -352.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -17.87
Qtrly Earnings Growth 0
Operating Cash Flow -277 (M)
Levered Free Cash Flow -156 (M)

Stock Valuations

PE Ratio -8.18
PEG Ratio 0
Price to Book value 26.85
Price to Sales 0
Price to Cash Flow -10.05

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.